A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2,184
- 主要终点
- Time to Improvement of Influenza Symptoms
研究概览
简要总结
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients or their legal guardians who provide written informed consent to participate in the study on a voluntary basis. For adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements.
- •Male or female patients ≥ 12 years at the time of signing the informed consent/assent form.
- •Patients with a diagnosis of influenza confirmed by all of the following:
- •Fever ≥ 38ºC (axillary) during the predose examinations or within the 4 hours prior if antipyretics were taken
- •A positive rapid influenza diagnostic test (RIDT) result OR A patient with a negative RIDT may be enrolled if the patient reports contact with a known case of influenza within the prior 7 days and all other inclusion criteria are met.
- •At least 1 each of the following general and respiratory symptoms associated with influenza is present with a severity of moderate or greater:
- •i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)
- •The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:
- •Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
- •Time when the patient experiences at least 1 new general or respiratory symptom
- •If a women of childbearing potential, agrees to use a highly effective method of contraception for 3 months after the first dose of study drug
- •Patients will be considered at high risk* of influenza complications due to the presence of at least 1 of the following inclusion criteria:
- •Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)
- •Endocrine disorders (including diabetes mellitus)
- •Residents of long-term care facilities (eg, nursing homes)
- •Compromised immune system (including patients receiving corticosteroids not exceeding 20 mg of prednisolone or equivalent, and patients being treated for human immunodeficiency virus [HIV] infection with a CD4 count > 350 cells/mm³ within the last 6 months)
- •Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury)
- •Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms
- •Adults aged ≥ 65 years
- •American Indians and Alaskan Natives
- •Blood disorders (such as sickle cell disease)
- •Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
- •Morbid obesity (body mass index ≥ 40 kg/m²)
- •Women who are within 2 weeks postpartum and are not breastfeeding
排除标准
- •Patients with severe influenza virus infection requiring inpatient treatment.
- •Patients with known allergy to oseltamivir (Tamiflu®).
- •Patients unable to swallow tablets or capsules.
- •Patients who have previously received baloxavir marboxil.
- •Patients weighing ≤ 40 kg.
- •Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.
- •Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:
- •Postmenopausal women (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test)
- •Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
- •Patients with concurrent infections at the predose examinations requiring systemic antimicrobial therapy.
- •Patients with liver disease associated with hepatic impairment.
- •Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).
- •Patients with untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months.
- •Patients with immunosuppression following organ or bone marrow transplants.
- •Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic corticosteroids.
- •Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to the predose examinations.
- •Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
- •Patients with known creatinine clearance ≤ 60 mL/min.
- •Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
研究组 & 干预措施
Baloxavir Marboxil
Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
干预措施: Baloxavir Marboxil (Drug)
Baloxavir Marboxil
Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
干预措施: Placebo to Oseltamivir (Drug)
Oseltamivir
Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
干预措施: Placebo to Baloxavir Marboxil (Drug)
Oseltamivir
Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
干预措施: Oseltamivir (Drug)
Placebo
Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
干预措施: Placebo to Baloxavir Marboxil (Drug)
Placebo
Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
干预措施: Placebo to Oseltamivir (Drug)
结局指标
主要结局
Time to Improvement of Influenza Symptoms
时间窗: From Day 1 pretreatment up to Day 14
Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.
次要结局
- Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point(Days 2, 3, 4 (optional), 5, 6 (optional), and 9.)
- Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer(Day 1 to Day 9)
- Percentage of Participants With Positive Influenza Virus Titer at Each Time Point(Days 2, 3, 4 (optional), 5, 6 (optional), and 9)
- Change From Baseline in Virus RNA (RT-PCR) at Each Time Point(Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9)
- Change From Baseline in Virus Titer at Each Time Point(Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9)
- Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA(Day 1 to Day 9)
- Time to Cessation of Viral Shedding Determined by Virus Titer(Day 1 to Day 9)
- Time to Cessation of Viral Shedding Determined by Virus RNA(Day 1 to Day 9)
- Percentage of Participants Whose Symptoms Were Improved at Each Time Point(12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment)
- Time to Alleviation of Symptoms(Initiation of study treatment up to Day 14)
- Time to Improvement of the Four Systemic Symptoms(Initiation of study treatment up to Day 14)
- Time to Improvement of the Three Respiratory Symptoms(Initiation of study treatment up to Day 14)
- Time to Resolution of Fever(Initiation of study treatment up to Day 14)
- Percentage of Participants Reporting Normal Temperature at Each Time Point(12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment)
- Body Temperature at Each Time Point(12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment)
- Time to Improvement of Individual Symptoms(Initiation of study treatment up to Day 14)
- Time to Return to Preinfluenza Health Status(Baseline to Day 14)
- Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection(Day 2 to Day 22)
- Percentage of Participants With Influenza-related Complications(Day 1 to Day 22)
- Percentage of Participants With Adverse Events (AEs)(From first dose of study drug to Day 22)